![](https://www.odt.co.nz/sites/default/files/styles/odt_portrait_medium_3_4/public/story/2020/05/pacific_edge_logo_090801.jpg?itok=HLdnjn72)
Last year the Canterbury and Waitemata health boards signed up to agreements, and now
Pacific Edge has just signed a commercial agreement with the MidCentral District Health Board, which was the first health board to try CX-bladder tests in mid-2013.
CX-bladder will now be incorporated into the standard of care by MidCentral from initial diagnosis to post-treatment surveillance, for patients across the Manawatu/Whanganui region.
Pacific Edge’s main marketing thrust is into the expansive United States markets, where care-providers to which the company is contracted have between them millions of potential clients.
For the non-invasive urine tests, to identify microscopic traces of blood, the Manawatu samples will be collected and sent to Pacific Edge’s certified Dunedin laboratory for analysis and a fast turnaround.